Early detection of pancreatic cancer
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is increasingly common. Screening for pancreatic cancer is not well established but might increase the chance of detection in the early stages. Summary: We conducted a literature search to summarize current recommendations and to give an overview of patient groups that may benefit from screening. In the general population, screening is not recommended because the low prevalence of PDAC renders any diagnostic tests non-predictive and because there is no direct evidence that links early diagnosis to improved survival. To date, novel approach...
Source: Oncology Research and Treatment - April 25, 2023 Category: Cancer & Oncology Source Type: research
OnkoImmun 18
Oncol Res Treat 2023;46:I –VIII (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - April 25, 2023 Category: Cancer & Oncology Source Type: research
Society Bulletins
Oncol Res Treat 2023;46:222 –226 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - April 24, 2023 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2023;46:219 –221 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - April 24, 2023 Category: Cancer & Oncology Source Type: research
Multiples Myelom: Langzeitergebnisse der MAIA-Studie
Oncol Res Treat 2023;46:216 –218 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - April 24, 2023 Category: Cancer & Oncology Source Type: research
Osimertinib: Hohe Wirksamkeit im Zentralnervensystem
Oncol Res Treat 2023;46:215 –215 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - April 24, 2023 Category: Cancer & Oncology Source Type: research
Prelims
Oncol Res Treat 2023;46:1 –6 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - April 17, 2023 Category: Cancer & Oncology Source Type: research
Identification and validation of CCNA2 and CCNE2 as potential biomarkers in small cell lung cancer
This study aimed to explore the potential biomarkers and therapeutic targets for SCLC.
Methods: After batch normalization of GSE40275, GSE1037, and GSE44447 datasets, R was used to screen SCLC's differentially expressed genes (DEGs) and hub genes. We use immunohistochemistry(IHC) to assess the tissue's expression level of the hub gene. The clinical value of the hub gene was further evaluated based on the collected clinical-pathological data.
Results: In this study, a total of 230 DEGs (133 up-regulated and 97 down-regulated) were screened by the R package. The IHC showed that the expression of CCNA2 and CCNE2 in SCLC tis...
Source: Oncology Research and Treatment - April 14, 2023 Category: Cancer & Oncology Source Type: research
Early versus delayed tumor specific therapy and survival in patients with lung cancer: a retrospective study
Conclusions: An early initiation of cancer specific therapy was associated with a shorter survival time in palliative lung cancer patients, independent of the ECOG-PS and histological subtype. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - April 13, 2023 Category: Cancer & Oncology Source Type: research
Society Bulletins
Oncol Res Treat 2023;46:171 –176 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - April 4, 2023 Category: Cancer & Oncology Source Type: research
Society Bulletins
Oncol Res Treat 2023;46:171 –171 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - April 4, 2023 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2023;46:166 –171 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - April 4, 2023 Category: Cancer & Oncology Source Type: research
